Metagenomi, Inc. Common Stock (MGX) is a Biotechnology company in the Healthcare sector, currently trading at $1.43. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is MGX = $15 (+914% upside).
Valuation: MGX trades at a trailing Price-to-Earnings (P/E) of -0.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.06.
Financials: revenue is $25M, +41.8%/yr average growth. Net income is $88M (loss), growing at -27.8%/yr. Net profit margin is -348.5% (negative). Gross margin is 78.9% (-11 pp trend).
Balance sheet: total debt is $41M against $159M equity (Debt-to-Equity (D/E) ratio 0.26, conservative). Current ratio is 7.22 (strong liquidity). Debt-to-assets is 18.4%. Total assets: $221M.
Analyst outlook: 4 / 5 analysts rate MGX as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
